Jon Faiz Kayyem, Director at Inhibrx Biosciences, Inc. (INBX), bought 573,572 shares at $17.90 ($9.9M) on 2024-06-03, disclosed to the SEC on 2024-06-04.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.14 | 70,193 | $1.1M | 11.5% |
| 2 | $16.14 | 70,193 | $1.1M | 11.5% |
| 3 | $16.61 | 46,792 | $777K | 7.9% |
| 4 | $16.61 | 46,792 | $777K | 7.9% |
| 5 | $17.90 | 80,738 | $1.4M | 14.7% |
| 6 | $17.90 | 80,738 |
| $1.4M |
| 14.7% |
| 7 | $17.44 | 65,337 | $1.1M | 11.6% |
| 8 | $17.44 | 65,337 | $1.1M | 11.6% |
| 9 | $18.24 | 23,726 | $433K | 4.4% |
| 10 | $18.24 | 23,726 | $433K | 4.4% |
| Total | $17.18 avg | 573,572 | $9.9M | 100% |
| Filing → |
| INBX | BUY | 2026-09-08 | $568K | — | Filing → |
| INBX | BUY | 2024-11-22 | $1.5M | — | Filing → |
| INBX | BUY | 2024-06-07 | $2.0M | — | Filing → |